Role of Apo-lipoprotein A1 as cardiac biomarker for severity of coronary atherosclerosis
Objective Coronary heart disease (CAD) is the most prevalent chronic disease and the main leading cause of death in the world, with more than half a million newly diagnosed CAD patients each year. The development of atherosclerosis involves the interaction of multiple metabolic and cellular processe...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nab'a Al-Hayat Foundation for Medical Sciences and Health Care - Press
2016-01-01
|
| Series: | Journal of Contemporary Medical Sciences |
| Subjects: | |
| Online Access: | http://jocms.org/index.php/jcms/article/view/49 |
| _version_ | 1811196846574403584 |
|---|---|
| author | Fadhil Jawad Al-Tu’ma Zainab Abdul-Hussei Abd-Yaser Karim Obais Al-Naffi |
| author_facet | Fadhil Jawad Al-Tu’ma Zainab Abdul-Hussei Abd-Yaser Karim Obais Al-Naffi |
| author_sort | Fadhil Jawad Al-Tu’ma |
| collection | DOAJ |
| description | Objective Coronary heart disease (CAD) is the most prevalent chronic disease and the main leading cause of death in the world, with more
than half a million newly diagnosed CAD patients each year. The development of atherosclerosis involves the interaction of multiple
metabolic and cellular processes. Central to this are disorders of lipoprotein metabolism. Apolipoprotein A-I is the major protein component
of high-density lipoprotein (HDL) in plasma. Chylomicrons secreted from the intestinal enterocyte also contain Apo A-I, but it is quickly
transferred to HDL in the blood stream. The aim of this study is to determine if Apo-A1 can be used as indicator to severity and extent of CAD.
Methods This study was conducted in cardiac catheterisation unit at Al Hussein Medical city from November 2014 to September 2015. It included
76 patients (49 males and 27 females) who presented with signs and symptoms of CAD and have undergone angiography. Control group
consisted of 20 healthy subjects (14 males and 6 females) matched for age and BMI. Serum levels of Apo-A1 were measured in both groups. After
coronary angiography was done for all patients, the extent and severity of CAD was correlated with serum levels of Apo-A1. The extent of CAD
was determined by angiography, according to number of coronary arteries involved and degree of narrowing in coronary artery diameter.
Results The angiographic finding in patient group was normal in 22 patients (28.9%), single vessel involvement in 15 patients (19.7%), two
vessels disease in 15 patients (19.7%) and three vessels disease in 18 patients (23.8%). The left main stem disease (LMD) was found in
6 patients (7.9%). There was no significant difference in the serum level of Apo-A1 between patient with CAD and control group (P = 0.147).
There was no significant correlation between serum level of Apo-A1 and the extent CAD (r = 0.004, P = 0.975).
Conclusion There was no significant difference in serum level of Apo-A1 between the patients group and the control group. Also, there was
no significant correlation between serum level of Apo-A1 and the extent of CAD. |
| first_indexed | 2024-04-12T01:06:19Z |
| format | Article |
| id | doaj.art-31cf100c1a6140aebdaf72b8fef7b5e5 |
| institution | Directory Open Access Journal |
| issn | 2413-0516 |
| language | English |
| last_indexed | 2024-04-12T01:06:19Z |
| publishDate | 2016-01-01 |
| publisher | Nab'a Al-Hayat Foundation for Medical Sciences and Health Care - Press |
| record_format | Article |
| series | Journal of Contemporary Medical Sciences |
| spelling | doaj.art-31cf100c1a6140aebdaf72b8fef7b5e52022-12-22T03:54:15ZengNab'a Al-Hayat Foundation for Medical Sciences and Health Care - PressJournal of Contemporary Medical Sciences2413-05162016-01-0114273037Role of Apo-lipoprotein A1 as cardiac biomarker for severity of coronary atherosclerosisFadhil Jawad Al-Tu’ma0Zainab Abdul-Hussei Abd-Yaser1Karim Obais Al-Naffi2Department of Biochemistry, College of Medicine, University of KerbalaDepartment of Biochemistry, College of Medicine, University of KerbalaDepartment of Internal Medicine, College of Medicine, University of KerbalaObjective Coronary heart disease (CAD) is the most prevalent chronic disease and the main leading cause of death in the world, with more than half a million newly diagnosed CAD patients each year. The development of atherosclerosis involves the interaction of multiple metabolic and cellular processes. Central to this are disorders of lipoprotein metabolism. Apolipoprotein A-I is the major protein component of high-density lipoprotein (HDL) in plasma. Chylomicrons secreted from the intestinal enterocyte also contain Apo A-I, but it is quickly transferred to HDL in the blood stream. The aim of this study is to determine if Apo-A1 can be used as indicator to severity and extent of CAD. Methods This study was conducted in cardiac catheterisation unit at Al Hussein Medical city from November 2014 to September 2015. It included 76 patients (49 males and 27 females) who presented with signs and symptoms of CAD and have undergone angiography. Control group consisted of 20 healthy subjects (14 males and 6 females) matched for age and BMI. Serum levels of Apo-A1 were measured in both groups. After coronary angiography was done for all patients, the extent and severity of CAD was correlated with serum levels of Apo-A1. The extent of CAD was determined by angiography, according to number of coronary arteries involved and degree of narrowing in coronary artery diameter. Results The angiographic finding in patient group was normal in 22 patients (28.9%), single vessel involvement in 15 patients (19.7%), two vessels disease in 15 patients (19.7%) and three vessels disease in 18 patients (23.8%). The left main stem disease (LMD) was found in 6 patients (7.9%). There was no significant difference in the serum level of Apo-A1 between patient with CAD and control group (P = 0.147). There was no significant correlation between serum level of Apo-A1 and the extent CAD (r = 0.004, P = 0.975). Conclusion There was no significant difference in serum level of Apo-A1 between the patients group and the control group. Also, there was no significant correlation between serum level of Apo-A1 and the extent of CAD.http://jocms.org/index.php/jcms/article/view/49coronary artery disease (CAD), Apolipoprotein A1, left main stem disease (LMD) |
| spellingShingle | Fadhil Jawad Al-Tu’ma Zainab Abdul-Hussei Abd-Yaser Karim Obais Al-Naffi Role of Apo-lipoprotein A1 as cardiac biomarker for severity of coronary atherosclerosis Journal of Contemporary Medical Sciences coronary artery disease (CAD), Apolipoprotein A1, left main stem disease (LMD) |
| title | Role of Apo-lipoprotein A1 as cardiac biomarker for severity of coronary atherosclerosis |
| title_full | Role of Apo-lipoprotein A1 as cardiac biomarker for severity of coronary atherosclerosis |
| title_fullStr | Role of Apo-lipoprotein A1 as cardiac biomarker for severity of coronary atherosclerosis |
| title_full_unstemmed | Role of Apo-lipoprotein A1 as cardiac biomarker for severity of coronary atherosclerosis |
| title_short | Role of Apo-lipoprotein A1 as cardiac biomarker for severity of coronary atherosclerosis |
| title_sort | role of apo lipoprotein a1 as cardiac biomarker for severity of coronary atherosclerosis |
| topic | coronary artery disease (CAD), Apolipoprotein A1, left main stem disease (LMD) |
| url | http://jocms.org/index.php/jcms/article/view/49 |
| work_keys_str_mv | AT fadhiljawadaltuma roleofapolipoproteina1ascardiacbiomarkerforseverityofcoronaryatherosclerosis AT zainababdulhusseiabdyaser roleofapolipoproteina1ascardiacbiomarkerforseverityofcoronaryatherosclerosis AT karimobaisalnaffi roleofapolipoproteina1ascardiacbiomarkerforseverityofcoronaryatherosclerosis |